Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease

Antiviral Therapy

Volumn 14, Issue 7, 2009, Pages 939-952

  Donne, Adam J ^a,b   Hampson, Lynne ^b   He, Xiaotong T ^b   Day, Philip J R ^b   Salway, Fiona ^b   Rothera, Michael P ^c   Homer, Jarrod J ^d   Hampson, Ian N ^b  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PROTEIN E6; TELOMERASE;

ARTICLE; CELL IMMORTALIZATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; KERATINOCYTE; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS CELL INTERACTION; VIRUS INFECTION; WART VIRUS;

ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; CYTOSINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; OFF-LABEL USE; PAPILLOMA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; RESPIRATORY TRACT NEOPLASMS; RISK FACTORS; RNA;

EID: 72249088429     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1421     Document Type: Article

References (76)

1. de Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh K Acad Geneeskd Belg 1996; 58:19-47.
2. Donne AJ, Hampson I, He XT, et al. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis. Head Neck 2007; 29:741-750. (Pubitemid 47265529)
3. Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant 2008; 12:790-795.
4. Yoshizaki T, Wakisaka N, Kondo S, et al. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol 2008; 80:879-882.
5. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. Highrisk adenovirus-infected pediatric allogeneic haematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12:219-227. (Pubitemid 351326925)
6. Cusack C, Fitzgerald D, Clayton TM, et al. Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11-year-old girl. Pediatr Dermatol 2008; 25:387-389. (Pubitemid 351813967)
7. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995; 121:1386-1391.
8. Inglis AF, Jr. Cidofovir and the black box warning. Ann Otol Rhinol Laryngol 2005; 114:834-835.
9. Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002; 21:2334-2346. (Pubitemid 34407293)
10. Sirianni N, Wang J, Ferris RL. Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005; 41:423-428. (Pubitemid 40387872)
11. Kramata P, Votruba I, Otova B, et al. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 1996; 49:1005-1011. (Pubitemid 26182989)
12. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4:928-940. (Pubitemid 41637695)
13. Shin KH, Park KH, Hong HJ, et al. Prevalence of microsatellite instability, inactivation of mismatch repair genes, p53 mutation, and human papillomavirus infection in Korean oral cancer patients. Int J Oncol 2002; 21:297-302.
14. Shin KH, Ahn JH, Kang MK, et al. HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways. Int J Oncol 2006; 28:209-215.
15. Band V, Dalal S, Delmolino L, et al. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J 1993; 12:1847-1852. (Pubitemid 23157700)
16. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109:157-162. (Pubitemid 38240914)
17. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV 16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11:813-825. (Pubitemid 44497177)
18. Vandesompele J, De PK, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:RESEARCH0034
19. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5:231-237. (Pubitemid 40314954)
20. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171:788-796.
21. Albright JT, Pransky SM. Update on the use of cidofovir for managing recurrent respiratory papillomatosis. ENT News 2003; 12:71-73.
22. Mammas IN, Sourvinos G, Michael C, et al. Human papilloma virus in hyperplastic tonsillar and adenoid tissues in children. Pediatr Infect Dis J 2006; 25:1158-1162. (Pubitemid 44900680)
23. Sisk J, Schweinfurth JM, Wang XT, et al. Presence of human papillomavirus DNA in tonsillectomy specimens. Laryngoscope 2006; 116:1372-1374. (Pubitemid 44181449)
24. Smith EM, Pignatari SS, Gray SD, et al. Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction. Arch Otolaryngol Head Neck Surg 1993; 119:554-557.
25. Mori N, Krensky AM, Ohshima K, et al. Elevated expression of CCL5/RANTES in adult T-cell leukaemia cells: possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax. Int J Cancer 2004; 111:548-557. (Pubitemid 39045322)
26. Uchihara JN, Krensky AM, Matsuda T, et al. Transactivation of the CCL5/RANTES gene by Epstein- Barr virus latent membrane protein 1. Int J Cancer 2005; 114:747-755. (Pubitemid 40344436)
27. Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001; 7:285-289. (Pubitemid 32183031)
28. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347:669-671. (Pubitemid 20356243)
29. Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003; 170:6348-6354. (Pubitemid 36682621)
30. Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998; 69:21-27. (Pubitemid 28452269)
31. Ulfarsson E, Karstrom A, Yin S, et al. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 2005; 11:4674-4680. (Pubitemid 41557184)
32. Girnita L, Girnita A, Brodin B, et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 2000; 60:5278-5283. (Pubitemid 30739789)
33. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55:249-252.
34. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005; 92:2097-2101. (Pubitemid 40966242)
35. Shellenberger TD, Mazumdar A, Henderson Y, et al. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res 2005; 65:11501-11509. (Pubitemid 41821708)
36. Garcia MJ, Pole JC, Chin SF, et al. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 2005; 24:5235-5245.
37. Ivanov I, Lo KC, Hawthorn L, et al. Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene 2007; 26:2873-2884. (Pubitemid 46701445)
38. Chen Y, Pacyna-Gengelbach M, Deutschmann N, et al. Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int J Cancer 2007; 121:1021-1027.
39. Lemaire F, Millon R, Muller D, et al. Loss of HOP tumour suppressor expression in head and neck squamous cell carcinoma. Br J Cancer 2004; 91:258-261. (Pubitemid 39037069)
40. Zhao LY, Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol 2003; 77:13171-13181. (Pubitemid 37494313)
41. Jang SI, Kalinin A, Takahashi K, et al. Characterization of human epiplakin: RNAi-mediated epiplakin depletion leads to the disruption of keratin and vimentin IF networks. J Cell Sci 2005; 118:781-793. (Pubitemid 40372586)
42. Goto M, Sumiyoshi H, Sakai T, et al. Elimination of epiplakin by gene targeting results in acceleration of keratinocyte migration in mice. Mol Cell Biol 2006; 26:548-558. (Pubitemid 43089767)
43. Lott DG, Krakovitz PR. Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2009; 119:567-570.
44. Eisenbeis JF, Sappington JM. The effect of cidofovir injection concurrent with surgical resection for adult onset recurrent respiratory papillomatosis. Laryngoscope 2009; 119 Suppl 1:S96.
45. Carvalho CM, Huot L, Charlois AL, et al. Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. Acta Otolaryngol 2009; 129:462-470.
46. Broekema FI, Dikkers FG. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2008; 265:871-879.
47. Poetker DM, Patel NJ, Kerschner JE. Cidofovir modulated gene expression in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2008; 72:1385-1392.
48. McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, doubleblind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117:477-483.
49. Lewis TE, Milam TD, Klingler DW, et al. Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer. Urol Oncol 2005; 23:407-412. (Pubitemid 41654507)
50. Wirtenberger M, Tchatchou S, Hemminki K, et al. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis 2006; 27:593-598. (Pubitemid 43372887)
51. Capurso G, Lattimore S, Crnogorac-Jurcevic T, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006; 13:541-558. (Pubitemid 43886676)
52. Riker AI, Enkemann SA, Fodstad O, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1:13.
53. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392:300-303. (Pubitemid 28155105)
54. Yoon S, Molloy MJ, Wu MP, et al. C6ORF32 is upregulated during muscle cell differentiation and induces the formation of cellular filopodia. Dev Biol 2007; 301:70-81. (Pubitemid 44958405)
55. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59:4681-4687. (Pubitemid 29428976)
56. Vaday GG, Peehl DM, Kadam PA, et al. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66:124-134. (Pubitemid 43191234)
57. Ek S, Bjorck E, Hogerkorp CM, et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 2006; 118:2092-2097.
58. Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122:769-776.
59. Kashibuchi K, Tomita K, Schalken JA, et al. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007; 14:789-794. (Pubitemid 47313274)
60. Fujita M, Furukawa Y, Tsunoda T, et al. Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res 2001; 61:7722-7726. (Pubitemid 33049355)
61. Xiang Q, Fan SQ, Li J, et al. Expression of connexin43 and connexin45 in nasopharyngeal carcinoma. Ai Zheng 2002; 21:593-596. [Chinese]
62. Hayashi E, Kuramitsu Y, Okada F, et al. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005; 5:1024-1032. (Pubitemid 40469032)
63. Suomela S, Cao L, Bowcock A, et al. Interferon alphainducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol 2004; 122:717-721. (Pubitemid 38471341)
64. Taguchi T, Kato Y, Baba Y, et al. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol Rep 2004; 11:421-426.
65. Dong A, Kong M, Ma Z, et al. Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells. Acta Biochim Biophys Sin (Shanghai) 2008; 40:497-504. (Pubitemid 351847346)
66. Liu W, Bloom DA, Cance WG, et al. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29:1096-1107. (Pubitemid 351958687)
67. Sroka IC, McDaniel K, Nagle RB, et al. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Prostate 2008; 68:463-476.
68. Oshikawa K, Yanagisawa K, Ohno S, et al. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med 2002; 165:1005-1009. (Pubitemid 34774672)
69. Shimada H, Kuboshima M, Shiratori T, et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007; 30:97-103.
70. Kim TJ, Choi JJ, Kim WY, et al. Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci 2008; 99:31-38. (Pubitemid 350239028)
71. Pinheiro C, Longatto-Filho A, Ferreira L, et al. Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma. Int J Gynecol Pathol 2008; 27:568-574.
72. Pinheiro C, Longatto-Filho A, Scapulatempo C, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008; 452:139-146.
73. Raman M, Earnest S, Zhang K, et al. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 2007; 26:2005-2014. (Pubitemid 46625802)
74. Park M, Dean M, Cooper CS, et al. Mechanism of met oncogene activation. Cell 1986; 45:895-904.
75. Liu Q, Gao J, Chen X, et al. HBP21: A Novel Member of TPR Motif Family, as a Potential Chaperone of Heat Shock Protein 70 in Proliferative Vitreoretinopathy (PVR) and Breast Cancer. Mol Biotechnol 2008; 40:231-240.
76. Jackson RS, Cho YJ, Liang P. TIS11D is a candidate proapoptotic p53 target gene. Cell Cycle 2006; 5:2889-2893. (Pubitemid 44953942)